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ABSTRACT 
NeuroElectric Therapy (NET) is a benign and rapid, non-pharmacological detoxification 
treatment for the chemical dependent, either in-patient or out-patient, using very small amounts 
of electric current transcranially, with electtodes applied above the mastoid process. The pocket­
size stimulator is used continuously for 7 to 10 days (3-4 days for nicotine), without supple­
mentary drugs. Within this treatment period it eliminates the acute symptoms and also amelio­
rates the Chtonic Withdrawal Syndrome, which otherwise could last 18 months or longer, to a 
very substantial degree. By the end of treatment, 95% of 102 consecutive patients claimed they 
were free of craving, 75% that they were free of anxiery. NET has a reported drop-out rate of 
1.6% over a period of seven years. The basis of this therapeutic success has been the marriage 
of precision clinical techniques to highly specific combinations of electrical current parameters, 
both developed over 20 years of reported clinical and research work. It is suggested that the 
mechanism of action may be the rapid restoration to normal of abnormal neurotransmitter levels 
by specific electrical signals. Clinical treatments and double-blind studies are briefly described 
and reviewed, with new data on sleep effects. 
KEYWORDS: NeuroElectric Therapy, addictions, withdrawal symptomatology, current 
parameters, chronic withdrawal syndrome, double-blind studies, sleep 
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INTRODUCTION 
NeuroElectric Therapy (NET) has its roots in the serendipitous discovery 20 years ago by Dr. H. L. Wen (a surgical colleague of one of the authors), in the Hong Kong hospital where she was head of surgery. 
It was observed that the electroacupuncture analgesia under investigation as a 
replacement for general anesthesia also brought a short one-hour cessation of 
withdrawal symptomatology in some opioid addicted patients. After receiving 
the electroacupuncture, they volunteered the information that not only had 
their withdrawals stopped (since they could not obtain their regular supply of 
drugs whilst in hospital), but that the treatment had made them feel as if they 
had had a compensatory dose of their opium or heroin. 1 
Several highly trained Chinese acupuncturists in Hong Kong then attempted to 
reproduce this rapid detoxification from opioids, using traditional acupuncture 
techniques, without success. They could achieve rapid improvement in acute or 
chronic pain conditions, but in chemical dependency only a slow amelioration 
of some symptoms over a period of several weeks or months was possible. 
The Chinese pulse generator used for the electroacupuncture coincidentally 
could deliver an electrical signal of only III Hz (pulses per second), a frequency 
later found to be within the range appropriate for opioid detoxification. 2 
Experiments with a re-designed stimulator which could produce 250 Hz, 
elicited from addicts that they experienced a distinct euphoria which the 
previous treatments had not induced. This discovery suggested that different 
parameters could lead to different clinical effects and Dr Patterson became 
convinced it was the electrical component of the treatment which had signifi­
cant influence in withdrawal cessation, and not the acupuncture system which 
had never proved successful in treating the widespread opium use of earlier 
regimes in China. 
Several months later, in London, UK, we began using adhesive electrodes 
instead of needles for transmitting current, to avoid both pain and risk of 
infection.3 Also, the Chinese pulse generator was found to have an inadequate 
range of parameters for other addictive substances. For example, a patient 
addicted to methadone and Ritalin (the stimulant, methylphenidate) claimed 
that his craving for methadone disappeared by the third day of treatment, but 
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that his Ritalin craving was totally unaffected. It was only after developing a 
new stimulator, with a wider range of specifications, that it was possible to 
relieve the Ritalin craving with 2,000 Hz, a frequency deduced from literature 
emanating from Russia and Eastern Europe where bioelectricity had been 
practiced for many years. However, it was observed that such high frequencies 
must be used with knowledge of their responses, to avoid undesirable side effects 
such as agitation, disorientation or hallucinations. 
With the discovery of the brain's endogenous opioids, the endorphins, in 1975,4 
and the subsequent worldwide burgeoning research into the relationship 
between different neurotransmitters and various addictive chemicals,S it became 
evident that the modus operandi of electrical stimulation in chemical dependency 
lay mainly in its effects on the reproduction or utilization of the relevant 
neurotransmitters or neuromodulators6 when these are in diminished produc­
tion or availability due to the receptors on brain cells being constantly occupied 
by exogenous substances. The function of the endorphins is related to pain 
control, emotion and motivation, and stimulation of the endorphins therefore 
affects either or all of these to a greater or lesser degree. 
ANIMAL RESEARCH 
With a stimulator that could provide a large range of clinically useful electrical signals-the first of eight increasingly advanced designs to date (1993) to meet chemically complex requirements-it 
became possible to investigate clinically, and later scientifically, the signifi­
cance of each of the current components, and their relationship to each other 
in the context of addiction treatments. The development of neurotransmitter 
research by other investigators, in particular, the effects of specific electrical 
signals on neurotransmitter production and other functions, in vitro as well 
as in vivo7-19 (see Table 1), provided an increasingly clearer picture of the 
probable neurochemical mechanisms of NET.20,21 For example, it has been 
shown in humans that cerebrospinal fluid (CSF) p-endorphin levels can be 
raised by percutaneous,22 transcutaneous,23 or direct brain stimulation,24 and 
that they will spontaneously return to their normal base level within 90 
minutes in non-pain subjects,23 that is, they cannot exceed the body's natural 
metabolic ceiling. 
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Table I 
System and Parameter Influence of the electrical signals. 

A list of some recent relevant research. 

System Parameter Reference 
Salivary gland Frequency, Goodman, et. al. 19877 
gene transcription wave-shape 
Salivary gland and Frequency, Goodman & Henderson 19888 
fibroblast wave-shape, Bourguignon & 
protein synthesis intensity Bourguignon 19879 
Salivary gland protein Frequency Jones & Wilson 1985 10 
secretion 
Bone cell cAMP levels 	 Intensity Korenstein, et. al. 198411 
Chick brain calcium efflux Frequency Blackman, et. al. 198912 
and chick chondrocyte Bassett, et. aL 197913 
calcium influx 
Rabbit spinal cord Frequency Han & Sun 199014 
enkephalin and 
dynorphin release 
Chick sensory ganglion Frequency, Sisken, et. al. 1981 15 
neurite outgrowth wave-shape 
Adult newt limb Wave-shape Smith & Pilla 1981 16 
regeneration 
Chick embryogenesis 	 Intensity, Ubeda, et. al. 198317 
wave-shape 
Acetylcholine & dopamine Frequency Cubeddu & Hoffman 1983 18 
release in rabbit striatum 
H-noradrenaline release in Frequency Dixey & Rein 198219 
donal nerve cell line 
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Cheng and Pomeranz studied electro-analgesia in mice, using different pulse 
frequencies (0.2, 4 or 200 Hz). The least level of analgesia resulted from 0.2 
Hz and the greatest from 200 Hz-a frequency that is often used in NET for 
pain, but again such high frequency must be used with care. Cheng and 
Pomeranz found they could completely reverse the 4 Hz analgesia with 
naloxone, indicating endorphinergic mechanisms, but there was no inhibition 
at 200 Hz. (A later study by Han, et. al. did show some reversibility at 100 
Hz with higher doses of naloxone.)25 Conversely, parachlorophenylalanine (a 
serotonin formation inhibitor) partially blocked 200 Hz analgesia but showed 
no effect at 4 Hz, suggesting that the action of the higher frequency may be 
serotonergic in origin.26 Our own animal work showed significant effects on 
the serotonergic system at both 10 Hz and 500 Hz.21 
In 1990, Han and Sun reported that different CNS neuropeptides 
(metenkephalin and dynorphin A) were released in rats by different frequen­
cies of electrical stimulation (ES), 14 2 and 100 Hz respectively. In 1991, this 
effect was confirmed by Han and Terenius, in the CSF of humans who were 
given transcutaneous electric stimulation (TENS) through peripheral skin 
electrodes placed over certain acupuncture points, at either 2 Hz or 100 Hz.27 
I n the early days of NET, physiologists often argued that nerves could not respond to frequencies higher than 200 Hz at most, yet there was no doubt at all about the clinical response to 2000 Hz, which is the highest 
unmodulated frequency used in NET for patients, to avoid the risk of 
diathermy effects which begin about 6000 Hz. Several in vitro experiments 
confirmed that neurons could respond to such high frequencies;19 and recently 
Han reported an investigation into the effects of 2000 Hz (2kHz) and 5000 
Hz (5kHz) on the tail flick latency (TFL) of rats. 28 A significant increase in 
TFL was obtained after 10 minutes of electrostimulation and lasted for the 
whole stimulation period of 30 minutes, although somewhat less at 5kHz than 
2kHz. It is interesting that 20 mg/kg of the opioid antagonist naloxone 
produced a 500/0 blockade of the antinociception induced by 2kHz but not 
from the 5kHz stimulation, indicating different physiological mechanisms. 
In addition, Russian colleagues, in particular Professor Valeri Lebedev of the 
Pavlov Institute in St. Petersburg, have described their extensive research, still 
mostly in Russian literature, to find the optimum parameters which will induce 
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endorphinergic systems in a variety of animal species, and particularly in 
humans, using transcranial stimulation. They have concluded that 77.5 Hz is 
the optimum in humans. 29 
CLINICAL RESEARCH 
I n the early days of our research, in the seventies, (see UN Bulletin)30 we experimented clinically with many different parameters of electrical current within each course of treatment, then estimated which frequencies and 
which size and shape of pulse seemed to bring the greatest symptomatic relief 
from withdrawals to that individual. Finally, we analyzed the treatment response 
to each different group of drugs abused, and found there was a distinct correla­
tion between the optimum type of electrical signal and the drug of addiction. 
Within the opioid group, there were even differences between the different 
opioids; for example, the optimum basic frequency for heroin was found to be 
90 Hz, for Palfium (dextromoramide) 150 Hz and for methadone 70 Hz. This 
has been confirmed repeatedly by experienced members of our trained staff, 
and such empirical clinical research still continues. 
The advantages of NET were found to lie not only in rapid, drug-free detoxi­
fication, but also the patients' emergence from the 7 to 10 days' treatment with 
a clear, alert mind, and showing signs of the beginning of motivation towards 
living a more constructive life. 1. S. Cooper of New York has also emphasized 
the beneficial behavioral effects of electrostimulation (ES) when used to treat 
intractable epilepsy or spastic conditions, with electrodes implanted on the 
cerebellum, even if the epilepsy was not diminished,31 and R. G. Heath in 
New Orleans has independently reported similar encouraging results from ES 
with implanted electrodes, in intractable behavioral disorders due to epilepsy 
or trauma, and in severe depression.32 A few anecdotal cases of clinical improve­
ment have now been reported by Childs of Austin, Texas, using surface 
(transcranial) ES in cases of post-traumatic amnesia and spasticity.33,34 
Only one double-blind study of NET has been published to date, conducted 
by the Philadelphia Addiction Research Center, in cooperation with two of the 
authors.35 It should be emphasized that all treatments given were below the 
level of sensation in order to make the study truly blind. Only the staff who 
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were trained in the use of the research model of the MEGANET stimulator 
and pre-set the codes were able to gain access to the displays showing the actual 
amount of current and voltage being given to each subject. It is interesting 
that 42 of the 43 addicted subjects in the study showed clinical improvement, 
and completion rate was 88%, yet by statistical analysis there was no signifi­
cant difference between placebo and active treatment groups. However, the 
trained technicians who assessed the subjects twice daily and were blind to the 
groupings, correctly guessed the active treatment subjects 760/0 of the time, 
indicating that clinical differences were conspicuous. 
The explanation for this could lie in the fact that the placebo treatment 
provided 0.2 milliAmps(mAmps) of current in order to produce a display on 
the stimulator which was exactly the same as for those receiving active 
treatment. Before the trial, it was thought that such a small amount of current 
would not effect a clinical response. All active treatments were given at a sublim­
inal level of sensation, which previous research had shown to be effective in 
detoxification. Each person has a different subliminal level of current, presum­
ably due to differences in skin and bone resistance. In this trial, the sublim­
inal level ranged from 0.6 to 4.3 mAmps. 
T o elucidate the relationship between current level and treatment efficacy, one of us (L. Patterson) conducted an open investigation in an Addiction Treatment Center, with signed patient consent, into the effect 
of a standard microcurrent level of output (1.0 mAmps as suggested by FDA 
for CES) on withdrawal symptomatology, with alcohol as the primary substance 
of addiction, using the MEGANET VII stimulator. The results indicated that 
microcurrent levels of output could noticeably ameliorate withdrawal sympto­
matology; the further removed the patient's liminal level was above the 1.0 
mAmps standard, the less efficacious the stimulation, the more overt the 
underlying anxiety/aggression, and the more profound the 'swings' that occur 
during the NET treatment.36 
Two patients in the Philadelphia double-blind study were treated twice. The 
two methadone patients who relapsed and returned for a second treatment 
during the trial period, by sheer chance were given one active and one placebo 
treatment each. One of these two relapsers had very severe withdrawal 
symptoms with his first treatment which the later analysis showed to be placebo: 
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his second treatment several months later was active and virtually symptom 
free. The significance of this lies in the fact that this patient required the highest 
current of all 43 subjects to obtain a liminal level of sensation, and was therefore 
unlikely to receive any benefit from a 0.2 mAmps output. Dummy leads will 
be used in all future blinded studies to clarify the issue of the effectiveness of 
minimal current as compared to zero current. 
O nly one of the hospitals involved in this double-blind trial recorded the sleep ratings (for active subjects n = 8 and placebo n 10), which have not been previously reported. Duration of sleep over 6 hours was 
rated 0 and less than 2 hours as 3; quality of sleep was rated 0 for peaceful 
and 3 for very restless. On average, the active subjects slept longer than the 
placebo group, but using the one tailed t-test the difference was not significant 
(p > 0.1). However, the quality of sleep was significantly better in the active 
group compared to the placebo (p < 0.02). Methadone, widely used as a heroin 
substitute, is notorious amongst addicts for its prolonged withdrawal insomnia. 
Under NET, patients have been safely and rapidly detoxified-within 10 
days-from daily drug dosages as large as 300 milligrams prescribed heroin to 
10 grams of street heroin; 0.5 to 10 grams cocaine; 40 to 800 mg methadone; 
and various narcotic and psychotropic prescription medications up to 70 tablets 
daily. Up to 8 years after treatment, 800/0 of 93 traced patients claimed that 
they were still drug-free, 780/0 that they were alcohol-free.37 The reported drop­
out rate (DaR) of 1.60/0 in NET treated addicts over a period of seven years, 
compared to the 35 to 900/0 DaR reported for any other treatment process, 
emphasizes not only the success of the treatment but also its acceptability to 
patients. 
NET includes not only multiple applications of differing electrical parameters, 
but also their carefully timed applications to provide the optimum advanta­
geous clinical response. Twenty years of clinical investigation have demonstrated 
that even minute alterations of electrical parameters can have a large impact 
on the clinical outcome. 
The Acute Withdrawal Syndrome (AWS) or Abstinence Syndrome (AS) varies 
with each group of psychoactive drugs, as described earlier! (pp. 245-248), but 
the most common and basic symptoms are those listed by Kolb and 
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Abstinence Syndrome indicators: 
44 'Yen sleep' Anorexia 
40 Yawning Gooseflesh 
36 Rubbing nose Restlessness 
32 Rhinnorhea Nausea 
28 Perspiration Shivering 













1 2 3 4 5 6 7 8 9 10 
Day of NET 
Figure 1. Abstinence Syndrome (AS) indicators: Mean ofdaily means of the AS for all 
addictions combined (n 102) for one year (1980), based on Himmelsbach's categoriza­
tion.38 Each of the 19 signs and symptoms (as in figure) were recorded on a 0-4 point 
scale, totalling a possible 76points. The dominant AS indicators varied between patients; 
it was rare jor anyone to experience all the symptoms. The highest mean recorded was 9 
points out of 76 because all drugs were totally stopped on admission and NET started 
immediately; thus withdrawal symptomatology was kept at a minimum from the 
beginning. Recordings were made objectively by trained observers and corresponded closely 
with subjective ratings. 
Himmelsbach for opiates38 (see Figure 1). Eventually the body will restore itself 
to physiological normality without any treatment at all, but this stage, known 
as the Chronic (or Protracted) Withdrawal Syndrome (CWS) may drag on for 
18 months to 2 years after stopping drugs such as methadone, alcohol or 
tranquilizers. Some describe it as resembling a low-grade depressive syndrome, 
with a variety of specific symptoms associated with particular drugs. The CWS 
is a major cause of relapse to drug or alcohol use, the other common reason 
being the lack of an appropriate psychosocial or psychospiritual support system. 
All patients regard the rapid relief NET provides from the CWS as being of 
much greater consequence than the speedy elimination of the acute 
symptoms. 
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Another important factor to emerge from the research is that the most crucial 
aspect to any successful detoxification by ES is the delivery of the correct 
combination of specific and precise electrical signals at the relevant times in the 
treatment program. In addition to the basic pulse frequency for detoxification 
for each different group of psychoactive drugs, several other frequencies are 
utilized for relief of symptoms such as dysphoria or craving. The output is 
subliminal at 0.9 to 3.5 mAmps for the majority of subjects, but some patients 
prefer supraliminal current for psychological comfort. The significance of the 
correlation between the liminal level of output and effectiveness of treatment 
has not yet been finally determined. 
T he precision techniques underlying this successful detoxification include the placement of electrodes on a specific area above the mastoid process; and, most important of all, the clinical techniques, ensuring correct 
polarity. If the patient is right-handed, the positive electrode is placed behind 
the right ear; if left-handed, the positive electrode is placed behind the left ear. 
The apparent association with the dominant hemisphere of the brain has been 
established empirically although not yet fully understood, and if not adhered 
to, the therapeutic effect will be completely negated. Other independent researchers 
have since confirmed this finding in their own animal research, emphasizing 
that in rats the positive electrode must be applied to the right ear in order to 
reduce the withdrawal symptoms, but offering no explanation for this phenom­
enon.39,40 
The ability of NET to rapidly restore a healthy sleep pattern-usually without 
any use of sleep medication-is one of its important features. Not originally 
used as a sleep aid, in 1974 a heavily addicted patient, whose daily 800 mg of 
methadone had been abruptly stopped on commencing NET, fell asleep while 
using the stimulator, and, continuing to wear it, slept the whole night through. 
Since then, considerable investigation has gone into developing the electrical 
signal optimally effective in inducing sleep during the associated insomnia of 
withdrawal. 
NET has been noted by the authors for some time to be clinically most effica­
cious when the receptors are as clear as possible of exogenous substances. The 
technique of commencing stimulation only when the patient is in acute 
withdrawal is now standard procedure with all NET treatments. When Figure 1 
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Table II 
Example of a first day withdrawal rating scale in 1991, 
a combination of subjective and objective observations. 
Male patient using heroin 1 1/2 grams daily. 
OPIATE WITHDRAWAL RATING SCALE 
TREATMENT DAY: One MEGANET Unit No: 
Narne: Deleted Date: Deleted 
Drug (Check one): X Heroin Methadone Cocaine Other 
Please enter time, and rate severity of withdrawal and craving on 
a scale of 0 to 10. 
RATING SCALE: 
NONE SEVERE 











Loss of appetite 





































Total: 97 19 0 
Note: Rating on admission 97. Remained symptom-free after treatment. 
was made on 102 consecutive patients treated in 1980, NET was commenced 
before the patients went into acute withdrawals (hence the low initial level of 
symptoms), but with the present regime, the zero level of symptomatology is 
reached considerably more rapidly, as demonstrated in Table II. 
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Unlike other forms of ES application in detoxification, NET is used continu­
ously when possible, day and night, for the first half of the treatment period 
(approximately 5 days), in order to prevent re-emergence of symptoms. 
PARAMETERS OF CURRENT 
T he use of a rectangular current wave form in NET emerged as a result of clinical comparison with a sinewave, which showed increased treatment benefit from the former. From personal communication with 
two fellow-researchers in the same field-Ellison of France and Lebedev of 
Russia-it was learned that they also arrived at their use of a rectangular wave 
by means of the same empirical approach. Both their and our independent and 
separate animal studies have reinforced the accuracy of this conclusion.41 
NET incorporates only an AC signal, with zero net DC component. Direct 
current (DC) may produce more rapid effect, but it also carries the risk of 
ionization of tissues, and sometimes of skin burns under the electrodes. NET 
provides a rectangular wave with a pulse-width of 0.22 msec (asymmetric but 
balanced) and modulated by a rapid sinewave for sleep. Also, while the NET 
stimulator has a pulse frequency range of 5 to 2,000 Hz, frequencies above 
200 Hz are used with caution for limited time periods only. 
With the development of increasingly sophisticated stimulators, each better 
equipped to deliver the more subtle variations of electrical signals required in 
the complex addiction treatment process, it became possible to increase clinical 
efficacy with a consistently smaller amount of current. While the individual 
response, based on each individual's differing skin and bone resistance, still 
dictates the amount of current each person receives, clinical experience has 
established that subliminal levels of current are at least as efficacious as supral­
iminal in eliciting a therapeutic response. However, where the minimal level 
required to obtain a clinical response lies is still under investigation. 
Long-term health effects have been carefully monitored. A follow-up study in 
1981, covering the eight years after NET was serendipitously discovered (260/0 
of the 93 patients traced had been treated more than 3 years previously), showed 
only beneficial side-effects, such as improved health, sleep and relationships 
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with family, and 79% were no longer addicted. All but one of the addiction­
free and three of the relapsed reported their health to be the same, or improved; 
in fact, 870/0 of the drug-free and 44% of the relapsed claimed actual improve­
ment. Full details of this follow-up are given in a 1984 issue of the Journal of 
Bioelectricity.37 
Transcranial ES, including NET, used appropriately and without concurrent 
medication, is both a safe and highly effective treatment modality for the detoxi­
fication of the chemically dependent, as reported by two independent 
groups.42,43 Long-term use of ES for chronic pain has been described as a 
"safe treatment" in an FDA investigation44 with many patients using it daily 
for many years. 
We know of no report suggesting any effect such as has been feared with long­
term exposure to electromagnetic fields (EMF) created by, for example, overhead 
power lines45 or even domestic appliances such as hair-driers. It has actually 
been claimed that "EMF-induced changes in immune cell biochemistry could 
affect the organism's immune response directly in either a negative or positive 
manner."46 Investigations are producing contradictory results47 and mostly 
reflect whole-body fields; the localized application of is conceptually 
simpler and provides opportunities for finer control. Besides, NET is given for 
a maximum of 10 days, and in the case of drug and alcohol abuse, let alone 
the 3 days for cigarette smoking, any possible risk would be greatly outweighed 
by the potential benefits. 
Nevertheless, careless or inappropriate use of such stimulation may endanger the individual if treated by an untrained person. It is for this reason that a fully pre-programmed, computerized stimulator has now 
been designed, with an accompanying Treatment Manual as a guide to the 
medical aspects of the treatment, so that mistakes are unlikely to be made by 
those who have an inadequate knowledge of bioelectricity or who do not have 
the time to study its many complexities in the field of addictions. The whole 
24 hour-a-day, up to 10-day NET program is incorporated in the device, and 
the associated software, which includes programs adapted for out-patient 
treatment. Individual treatment regimes for different conditions, derived from 
close clinical observation of all forms of addiction over a period of 20 years, 
are included in the software. These are available as separate applications for 
Subtle Energies • Volume 3 • Number 3 • Page 13 
each of the major substances of addiction, or in combinations of substances 
abused, which can be simply administered by medical supervisors. The unit is 
easily carried in a pocket. 
CLINICAL RESULTS 
Amongst the authors' early patients there were many musicians. Some of the most notable advances in NET in its formative stages derived largely from these experts in electronic music, who were interested in 
constantly manipulating the electrical parameters of the stimulator (all hand­
operated at that time) until they experienced what "felt right." A considerable 
amount of practical technical information in NET was derived from this 
musically inspired motivation. 1 Significantly, our later work with rats48,49 
demonstrated that those early subjective opinions as to what provided greatest 
withdrawal relief were confirmed experimentally as having the optimum 
measured effect using the Righting Reflex-a very accurate measurement In 
rats-of the speed of detoxification from various drugs (Table III). 
The clinical regime involved in NET, and developed over succeeding years, is 
portrayed in a 36-year-old single European male heroin addict given 7 days of 
NET after abrupt cessation of all drugs. His first drug use had been when he 
was 15 years old-amphetamines, Mandrax (methaqualone) and cannabis, 
advancing to develop a severe cocaine habit, smoking and intravenous (I/V) 
use-and finally heroin, using between 1 and 1.5 G daily. He went through 
multiple 'cold turkeys' by himself but only one supervised attempt at detoxifi­
cation, and he felt depressed and physically weak when off drugs. 
The withdrawal relief experienced here under NET (Table II) was unusually 
profound, but illustrates the difference in effect between the 1980 regime (as 
in Figure 1) when NET was commenced on admission, and the present 
technique of commencing NET only when symptoms of acute withdrawal are 
evident. The majority of patients experience between 50 and 75% reduction 
in withdrawal symptomatology compared to their previous experiences by a 
variety of different methods of withdrawal (this taking the place of a controlled, 
comparative group in our 7-year follow-up) with a minority experiencing 
between 75 and 95% reduction. Most of these figures represent a combination 
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Table III 
The Effect of Electrostimulation at Various Frequencies on the 
Hexobarbital (100mg/kg)-Induced Sleeping Times in Female 
Rats. Results represent mean ± S.D. for individual assays on 
six animals in each group. Two frequencies, either 10Hz 
(p < 0.001) or 500 Hz (p < 0.001) were most effective in 
decreasing the hexobarbital-induced sleeping time. However, 
an unmodulated frequency of 500 Hz must be used with 
caution. 
Percent 
Frequency (Hz) Sleeping Time (mins) Reduction in 
sleeping time 
1 61±12 23 
5 56±11 29 
10 46±08 42 
15 59±16 25 
20 57±06 28 
30 54±09 32 
90 68±06 14 
100 72±09 9 
200 74±13 5 
500 48±05 39 
1000 58±06 27 
of subjective and objective reporting. As can be seen from Table II, relief is 
almost immediate-between a half to two hours after commencement of NET, 
with all substances of addiction. 
Y et the full 7 to 10 days of NET is always given, whether as in-patient or out-patient treatment, partly because symptoms may recur unexpectedly, and partly because the rapid clearing of the mind 
compels the patient to begin facing up to the real problems that caused the 
drug use in the first place. The therapist thus has a crucial supplementary role 
to play in the full recovery during the brief treatment period, and should also 
take responsibility for arranging a continuing support system. To achieve this 
mental and emotional clarity, no medication is given, even for substances with 
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Table IV 
Assessments of some recent patients treated in Europe by NET. 
OIA On Admission. 010 = On Discharge. SCL-90 = Symptom 
Check List-90: Highest (worst) possible figure is 450 and lowest 
(best) is 90. 
SexlAge Substance of Days Beck Hamilton SCL-90 
Addiction NET Depression Anxiety 
OIA 010 OIA 010 OIAOID 
M 36 Heroin smoked 7 28 2 36 0 234 95 
M 28 Cocaine nasal 7 41 6 25 6 287 134 





a high risk of convulsion during withdrawal. This decision was made after 
observing, in the first convulsing addict treated, many years ago, that his convul­
sions stopped as soon as his epilepsy medication (Epanutin) and slow reduction 
of his phenobarbiturate dosage were discontinued. 
It is no longer an accepted premise that pharmacology-and especially 
psychopharmacology-is required by clinical necessity for the successful detoxi­
fication of the chemical dependent, as has been demonstrated by recent 
independent clinical trials in the USA.35 
Recently, we have begun to include a series of standard assessments as part of 
the admission routine, and repeat them prior to discharge. Table IV shows 
some typical results found in opiate and cocaine addicts treated by NET. This 
ability of transcranial electrical stimulation (ES) to substantially reduce psychic 
distress and aggression has been noted by other investigators (using different 
designs of stimulator, but again very specific current criteria), both in the field 
of affective disorders,50 and affective disorders found as part of the alcohol 
withdrawal syndrome.51 In the latter double-blind study, conducted in St. 
Petersburg, Russia, out of 2 matched groups of 10 volunteer alcoholics each, 
who had all been abstinent for 3-4 weeks, the decrease in both depression 
and anxiety, measured by 5 standard assessments, was statistically significant 
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(p < 0.01), with a corresponding rise in the MAO-B in blood platelets (p < 0.05) 
and in GABA, in the active treatment group compared to the control. 
REPRESENTATIVE CASE-HISTORIES 
NET's rapidity of detoxification from prescribed drugs is equally effective, 
provided the current parameters are appropriate for that group of drugs. A 
young woman in her early thirties, on prescribed 6 mg Ativan (a benzodi­
azepine) daily for 10 years, wrote 3 months after NET, "I could never have 
undergone withdrawal without NET because of the short span of time that it 
has taken. The actual experience of withdrawal is one of self-discovery and 
rebirth. Rebirth is an excruciatingly painful business. One's sense of awareness 
is increased to what initially seems to be an unbearable degree. I needed 
constant companionship during the month following the treatment. The 
psychological experience is that of an extended acid trip which is pretty fright­
ening if one feels stuck in it for quite a few weeks. Without NET it could 
have taken a couple of years and my life would have without a doubt been 
totally ruined. .. It's truly amazing after 10 years of 'blur' to have my memory 
back and all of my five senses in tip-top working order. People are constantly 
struck by my sense of optimism these days and my sense of purpose..." 
A 51 year old alcoholic arrived for treatment in a state of extreme intoxication. Drinking four bottles of sherry wine daily for one and a half years, in addition, her physician had prescribed concurrently 
three different antidepressant drugs in an attempt to reduce her alcohol 
intake. All drugs and alcohol were stopped abruptly, yet she experienced 
neither delirium tremens nor 'the shakes'. The alcohol craving disappeared 
on the third day of NET and both her appearance and behavior improved 
dramatically. 
A 65 year old business man, smoking over 60 cigarettes daily, had such severe 
emphysema that he was breathless even after taking a shower. For the previous 
20 years he had been trying every known treatment to stop the habit, without 
success. Six years ago, he received 4 days of NET treatment and hasn't smoked 
one cigarette since. In addition, his breathlessness has been markedly reduced. 
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CONCLUSION 

A fter two decades of reported clinical and investigative work, NET has been demonstrated to be a safe and highly effective alternative to the restricted unsatisfactory pharmacological approach to detoxifying 
addicts. NET promotes and expedites the rapid return of the normal physio­
logical functions and psychological stability which enhances the addicts' ability 
to benefit from relapse prevention programs. In fact, Figure 2, taken from a 
7 -year follow-up of NET patients,l shows that 42% of addicts who were drug 
or alcohol free at follow-up had had no structured rehabilitation at all-their 
freedom from relapse presumably due to the profound physiological effects of 
NET-although a friend or parent may well have acted as their post-detox 
"support system." 
Even in the USA, where methadone maintenance is still strongly promoted, it 
was reported in 1991 that not more than 140/0 of the clients 'kick off' (heroin) 
in the course of a methadone program. Over a period of 8 months to 3 1/2 
years at least 860/0 experience a relapse to illicit drugs at least once.52 
In 1981, de Leon reported that "when effectiveness (of rehabilitation) is defined 
in terms of heroin or methadone abstinence, less than 100/0 are judged 
successful, 10 years after treatment."53 And in 1990, Professor Kreek wrote that 
"in several follow-up studies it has been shown that more than 80 percent of 
former methadone-maintained patients, irrespective of the degree of the rehabil­
i tation, relapse to heroin or other narcotic use within 2 years of leaving 
methadone treatment. 54 
With the recent rapid increase of babies born with defects due to the mother's 
addiction, NET will be made available to addicted pregnant women as soon 
as possible. Research is presently being conducted at the University of Texas 
into the effects on the fetuses of pregnant rats while being administered NET 
daily throughout pregnancy. The small amount of literature available on using 
electrical stimulation in human pregnancies suggest that it may be a safe 
procedure. 55,56 
Recent reports in the USA state that heroin is becoming both purer (having 
risen from 5-10% in the last few years to over 400/0) and cheaper, indicating 
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2 weeks or less 3 to 8 weeks 2 to 4 months 
Period spent in "rehabilitation" after 10 days of NET 
Figure 2. Relationship between time spent in "rehabilitation" after completion of10 days 
ofNET, and long-term outcome (n=84). Statistically, the long-term outcome appears to 
be unaffected by the length of time spent in some kind of institution after completion of 
NET A t-test was performed to determine if there was a mean difference in the days of 
rehabilitation between addiction-ftee and re-addicted. The mean number of days for 
addiction-free was 10.92, and for the re-addicted, 10.35. The t-test was not significant 
(t = .16, df = 85, P > .05) indicating that the duration of rehabilitation is unrelated to 
long-term outcome after NET However, a short period of intensive "rehabilitation" may 
be ofvalue to some, depending on individual character and needs. All received counselling 
during the 10 days ofNET 
the possibility of a new epidemic. 57 With addiction-and especially poly­
substance addiction-on the increase world-wide, it is timely to consider a new 
bioelectronic approach to the medical treatment of the chemically dependent. 
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